At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 151 enrolled
Drug / intervention
RZL-012 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double Blind, Randomized, Three Arm, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of RZL-012 in Subjects Seeking for Submental Fat Reduction
In Brief
A Phase 2 clinical trial evaluating RZL-012 and Placebo for Submental Fat. Completed, enrolled 151 participants across 1 site.
Detailed Summary
A total of 135 eligible male or female subjects will be randomized according to a predetermined randomization scheme (1:1:1 ratio) to receive a single multi-injection treatment of high dose RZL-012, low dose RZL-012, or placebo on Day 0. They will be monitored for safety and efficacy over 84 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubmental Fat
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartJun 2021
Primary CompletionApr 2022
Study CompletionMay 2022
TodayJul 2026
First PostedApr 30, 2021
Enrollment StartJun 15, 2021
Primary CompletionApr 20, 2022
Study CompletionMay 31, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.2 years ago
Interventions
RZL-012drug
small synthetic molecule for submental fat reduction
Placebodrug
Placebo